Vivos Therapeutics Q1 EPS $(0.07) Beats $(0.18) Estimate, Sales $3.86M Miss $4.01M Estimate
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics (NASDAQ:VVOS) reported Q1 losses of $(0.07) per share, beating the $(0.18) estimate by 61.11%. Sales were $3.86M, missing the $4.01M estimate by 3.82%. This is an improvement over last year's Q1 results.
June 08, 2023 | 8:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Vivos Therapeutics reported better-than-expected Q1 EPS of $(0.07) but missed sales estimates at $3.86M.
Vivos Therapeutics reported a better-than-expected EPS, which is a positive sign for investors. However, the company missed sales estimates, which could offset the positive impact of the EPS beat. The overall impact on the stock price is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100